Should I buy or sell Kineta stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kineta in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KA shares. View KA analyst ratings or view top-rated stocks .

What is Kineta's stock price target for 2024?

1 analysts have issued 12-month price targets for Kineta's stock. Their KA share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 1,539.3% from the stock's current price. View analysts price targets for KA or view top-rated stocks among Wall Street analysts .

How have KA shares performed in 2024?

Kineta's stock was trading at $3.63 on January 1st, 2024. Since then, KA shares have decreased by 86.6% and is now trading at $0.4880. View the best growth stocks for 2024 here .

Are investors shorting Kineta?

Kineta saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 61,800 shares, a drop of 17.9% from the March 15th total of 75,300 shares. Based on an average daily trading volume, of 205,100 shares, the short-interest ratio is currently 0.3 days. Currently, 0.8% of the company's shares are short sold. View Kineta's Short Interest .

When is Kineta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KA earnings forecast .

How were Kineta's earnings last quarter?

Kineta, Inc. (NASDAQ:KA) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.10.

How do I buy shares of Kineta?

Shares of KA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KA

Kineta (KA) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free KA Stock Alerts

$0.49

+0.02 (+4.27%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.41
▼
$0.55
50-Day Range: $0.34
▼
$2.83
52-Week Range: $0.33
▼
$5.39

Volume: 848,256 shs
Average Volume: 290,058 shs
Market Capitalization: $5.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Kineta alerts:

Kineta MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,539.3% Upside
$8.00 Price Target
Short Interest: Healthy
0.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.41) to ($1.35) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.30 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Kineta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Kineta has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.82% of the float of Kineta has been sold short.
Short Interest Ratio / Days to Cover
Kineta has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Kineta has recently decreased by 17.93%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Kineta does not currently pay a dividend.
Dividend Growth
Kineta does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KA.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Kineta this week, compared to 1 article on an average week.
Search Interest
3 people have searched for KA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kineta insiders have not sold or bought any company stock.
Percentage Held by Insiders
29.80% of the stock of Kineta is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 30.32% of the stock of Kineta is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Kineta are expected to grow in the coming year, from ($1.41) to ($1.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kineta is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kineta is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kineta has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Kineta Stock (NASDAQ:KA)

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy, which is in preclinical development for advanced solid tumors, such as renal cell carcinoma, ovarian, and colorectal cancers. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.

KA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KA Stock News Headlines

April 18, 2024 | msn.com

Kineta (KA) Price Target Increased by 25.58% to 13.77

April 9, 2024 | finanznachrichten.de

Kineta, Inc.: Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 8, 2024 | globenewswire.com

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

March 22, 2024 | finanznachrichten.de

Kineta, Inc.: Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

March 21, 2024 | globenewswire.com

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

March 12, 2024 | globenewswire.com

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

March 1, 2024 | bizjournals.com

Kineta CEO laid off as cutbacks leave biotech with 4 employees

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

February 29, 2024 | msn.com

Kineta stock falls ~25.7% after co cuts workforce by 64%, including CEO

February 29, 2024 | globenewswire.com

Kineta Announces Restructuring and Exploration of Strategic Alternatives

February 22, 2024 | finance.yahoo.com

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

February 22, 2024 | globenewswire.com

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

February 14, 2024 | finance.yahoo.com

Kineta to Present at Upcoming Investor Conferences

February 14, 2024 | globenewswire.com

Kineta to Present at Upcoming Investor Conferences

February 7, 2024 | stockhouse.com

Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series

January 29, 2024 | finance.yahoo.com

KA: Phase I/II Update

January 17, 2024 | finanznachrichten.de

Kineta, Inc.: Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

December 13, 2023 | finance.yahoo.com

Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer

December 12, 2023 | finance.yahoo.com

Kineta to Present at the Life Sciences Investor Forum December 14th

November 28, 2023 | finance.yahoo.com

Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023

November 9, 2023 | finance.yahoo.com

Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit

November 8, 2023 | markets.businessinsider.com

Buy Rating for Kineta Backed by Promising Drug Trials and Solid Financial Performance

November 7, 2023 | msn.com

KA: Third Quarter Results - MSN

November 7, 2023 | finance.yahoo.com

KA: Third Quarter Results

November 6, 2023 | benzinga.com

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

November 6, 2023 | finance.yahoo.com

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

See More Headlines

Receive KA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kineta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KA
CUSIP: N/A
CIK: 1445283
Web: www.kinetabio.com
Phone: (206) 378-0400
Fax: N/A
Employees: 11
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $8.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +1,545.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,100,000.00
Net Margins: N/A
Pretax Margin: -258.65%
Return on Equity: -453.89%
Return on Assets: -118.90%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 0.85
Quick Ratio: 0.85

Sales & Book Value

Annual Sales: $5.44 million
Price / Sales: 0.98
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.29 per share
Price / Book: 1.68

Miscellaneous

Outstanding Shares: 10,960,000
Free Float: 7,695,000
Market Cap: $5.33 million
Optionable: Not Optionable
Beta: 0.52

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Craig W. Philips (Age 63)
President
Comp: $485.79k
Ms. Pauline Kenny Esq. (Age 50)
J.D., Advisor
Comp: $349.72k
Mr. Keith A. Baker (Age 57)
Chief Financial Officer
Dr. Thierry Guillaudeux Ph.D. (Age 57)
Chief Scientific Officer
Gary Gentges
Executive Vice President of Corporate Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kineta stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kineta in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KA shares.
View KA analyst ratings or view top-rated stocks.
What is Kineta's stock price target for 2024?: 1 analysts have issued 12-month price targets for Kineta's stock. Their KA share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 1,539.3% from the stock's current price.
View analysts price targets for KA or view top-rated stocks among Wall Street analysts.
How have KA shares performed in 2024?: Kineta's stock was trading at $3.63 on January 1st, 2024. Since then, KA shares have decreased by 86.6% and is now trading at $0.4880.
View the best growth stocks for 2024 here.
Are investors shorting Kineta?: Kineta saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 61,800 shares, a drop of 17.9% from the March 15th total of 75,300 shares. Based on an average daily trading volume, of 205,100 shares, the short-interest ratio is currently 0.3 days. Currently, 0.8% of the company's shares are short sold.
View Kineta's Short Interest.

When is Kineta's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our KA earnings forecast.
How were Kineta's earnings last quarter?: Kineta, Inc. (NASDAQ:KA) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.10.
How do I buy shares of Kineta?: Shares of KA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kineta (KA) Stock Price, News & Analysis

Kineta MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Kineta Stock (NASDAQ:KA)

KA Stock Price History

KA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™